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A B S T R A C T
Background
Corticosteroids used in addition to antituberculous therapy have been reported to benefit people with tuberculous pleurisy. However,
research findings are inconsistent and raise doubt as to whether such treatment is worthwhile. There is also concern regarding the
potential adverse effects of corticosteroids, especially in HIV-positive people.
Objectives
To evaluate the effects of adding corticosteroids to drug regimens for tuberculous pleural effusion.
Search methods
In April 2016, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (the Cochrane Library), MED-
LINE, Embase, LILACS, Current Controlled Trials, and the reference lists of articles identified by the literature search.
Selection criteria
Randomized controlled trials (RCTs) and quasi-RCTs that compared any corticosteroid with no treatment, placebo, or other active
treatment (both groups should have received the same antituberculous drug regimen) in people diagnosed with tuberculous pleurisy.
Data collection and analysis
Two review authors independently screened the search results, extracted data from the included trials, and assessed trial methodological
quality using the Cochrane ’Risk of bias’ tool. We analysed the data using risk ratios (RR) with 95% confidence intervals (CIs). We
applied the fixed-effect model in the absence of statistically significant heterogeneity.
Main results
Six trials with 590 participants met the inclusion criteria, which were conducted in Asia (three trials), Africa (two trials), and Europe
(one trial). Two trials were in HIV-negative people, one trial was in HIV-positive people, and three trials did not report HIV status.
Corticosteroids may reduce the time to resolution of pleural effusion. Risk of residual pleural effusion on chest X-ray was reduced by
45% at eight weeks (RR 0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials, low certainty evidence), and 65% at 24 weeks (RR 0.35,
95% CI 0.18 to 0.66; 237 participants, 2 trials, low certainty evidence).
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Compared with control, corticosteroids may reduce the risk of having pleural changes (such as pleural thickening or pleural adhesions),
on chest X-ray at the end of follow-up by almost one third (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials,low certainty
evidence), which translates to an absolute risk reduction of 16%.
One trial reported deaths in people that were HIV-positive, with no obvious difference between the groups; the trial authors’ analysis
suggests that the deaths observed in this trial were related to HIV disease rather than pleural TB (RR 0.91, 95% CI 0.64 to 1.31; 197
participants, 1 trial).
We found limited data on long-term functional respiratory impairment on 187 people in two trials, which reported that average
percentage predicted forced vital capacity was similar in the group receiving prednisolone and in the control group (very low certainty
evidence).
The risk of adverse events that led to discontinuation of the trial drug was higher in people with pleural TB receiving corticosteroids
(RR 2.78, 95% CI 1.11 to 6.94; 587 participants, 6 trials, low certainty evidence). The trial in HIV-positive people reported on six
different HIV-related infections, with no obvious differences. However, cases of Kaposi’s sarcoma were only seen in the corticosteroid
group (with 6/99 cases in the steroid group compared to 0/98 in the control group) (very low certainty evidence).
Authors’ conclusions
Long-term respiratory function is potentially the most important outcome for assessing the effects of adjunctive treatments for people
with pleural TB. However, the information on the impact of pleural TB on long-term respiratory function is unknown and could be
eclipsed by other risk factors, such as concurrent pulmonary TB, smoking, and HIV. This probably needs to be quantified to help
decide whether further trials of corticosteroids for pleural TB would be worthwhile.
P L A I N L A N G U A G E S U M M A R Y
What is tuberculous pleurisy and how might corticosteroids work?
Tuberculous pleurisy results from inflammation of themembrane that covers the lungs (the pleura) caused by exposure toMycobacterium
tuberculosis bacteria infecting the lungs. This results in a build up of fluid around the lung (pleural effusion) that causes pain and fever,
impairs breathing, and may lead to impairment of lung function in the long term.
Some clinicians believe that corticosteroids used in combination with antituberculous drugs can speed up the recovery fromTB pleurisy
and help to prevent long-term complications.
What the evidence shows
We examined the available evidence up to 13 April 2016 and included six trials with 590 people, which evaluated prednisolone given
with antituberculous treatment (ATT). One included trial was of high quality, while the rest had uncertainties regarding trial quality.
All the included trials were in adults; one trial included only HIV-positive people, two included only HIV-negative people, and three
did not report the HIV status of the participants.
Corticosteroids may reduce the time to resolution of the symptoms of TB pleurisy and the time to resolution of the pleural effusion on
chest X-ray (low certainty evidence). Corticosteroids may also reduce the risk of having signs of pleural scarring on chest X-ray (pleural
thickening and pleural adhesions) after the disease has resolved (low certainty evidence). There was not enough information about lung
function to be sure whether or not corticosteroids reduce the risk of lung function impairment after TB pleurisy (very low certainty
evidence).
Corticosteroids may increase the risk of adverse events leading to discontinuation of the trial drug (low certainty evidence). From one
trial in people living with HIV, there was no detectable increase in HIV-related conditions with corticosteroids, although cases of
Kaposi’s sarcoma were only seen in the corticosteroid group and numbers of participants and events were too small to rule out an effect
of corticosteroids (very low certainty evidence).
As the risk of disability and long-term illness after TB pleurisy is unclear, research looking at the association between TB pleurisy and
lung function impairment would be useful to inform future research into corticosteroids for TB pleurisy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Steroids compared with placebo for pleural TB
Patient or population: adults and adolescents with pleural TB
Settings: hospital care and community follow-up
Intervention: cort icosteroids
Comparison: placebo
Outcomes Illustrative comparative risks¹ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Corticosteroids
Residual pleural fluid on
chest X- ray at 8 weeks
62 per 100 33 per 100
(23 to 48)
RR 0.54
(0.37 to 0.78)
237
(2 trials)
⊕⊕©©1,2,3,4
low
Residual pleural fluid on
chest X- ray at 24 weeks
29 per 100 10 per 100
(5 to 19)
RR 0.35
(0.18 to 0.66)
237
(2 trials)
⊕⊕©©1,2,3,4
low
Pleural changes at the end
of follow-up
(pleural adhesions or pleu-
ral thickening on chest
X-ray; follow-up 6 to 24
months)
50 per 100 36 per 100
(29 to 46)
RR 0.72
(0.57 to 0.92)
393
(5 trials)
⊕⊕©©5,6,7
low
Long- term functional res-
piratory impairment (> 6
months)
- - Average percentage pre-
dicted FVC sim ilar in cort i-
costeroid and control groups
187
(2 trials)
⊕©©©8
very low
Adverse events leading to
treatment discontinuation
(follow-up 6 to 24 months)
1 per 100 3 per 100
(1 to 7)
RR 2.78
(1.11 to 6.94)
590
(6 trials)
⊕⊕©©9,10
low
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HIV- related infections
(cryptococcal meningitis)
5 per 100 3 per 100
(1 to 12)
RR 0.59
(0.15 to 2.42)
103
(1 trial)
⊕©©©11,12
very low
HIV- related cancer (Ka-
posi’s sarcoma)
14 per 100013 180 per 1000
(1 to 316)
RR 12.87
(0.73 to 225.40)
103
(1 trial)
⊕©©©14,15
very low
¹The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluat ion; RR: risk rat io; TB: tuberculosis; FVC: forced vital
capacity
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Downgraded by one for risk of bias: of the four trials that reported this outcome, we excluded two trials f rom the f inal analysis
due to high risk of select ion bias, af ter a subgroup analysis suggested the pooled est imate including these studies could
be misleading (Bang 1997; Lee 1999). We judged this to be our best est imate of ef fect. However because we excluded
trials f rom this analysis this generates uncertainty, so we have downgraded the quality of the evidence.
2Not downgraded for inconsistency: heterogeneity in the original meta-analysis was likely due to dif ferences in study quality.
A subgroup analysis showed that stat ist ical heterogeneity disappeared when we excluded trials that were at high risk of
select ion bias.
3Downgraded by one for imprecision: the CI around the summary ef fect est imate is wide due to the small number of
part icipants and events in each included trial.
4Not downgraded for indirectness: the included trials were performed in dif ferent sett ings and t ime periods and used widely
available drugs and diagnost ic techniques. Although the trials did not include children, we did not downgrade as pleural TB is
less common in children than in adults. One trial included HIV-posit ive people, Elliot t 2004, and this trial contributed most of
the part icipants in the meta-analysis. When making recommendations relat ing to the use of cort icosteroids for pleural TB in
children or in HIV-negat ive adults, guideline panels may wish to consider downgrading for indirectness.
5Downgraded by one for serious risk of bias: we assessed two trials as at high risk of bias for randomizat ion method (Bang
1997; Lee 1999), and the other three trials were at unclear risk of bias (Galarza 1995; Lee 1988; Wyser 1996). Only Wyser 1996
reported that outcome assessors were blinded to the treatment allocat ion.
6Downgraded by one for serious imprecision: the CI around the summary ef fect est imate is wide, ranging f rom a maximum
risk reduct ion with steroids of 43% to a minimum risk reduct ion of 7%, which may not be clinically signif icant when weighed
against possible harms of steroids.
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7Not downgraded for indirectness: the trials were performed in a variety of sett ings, and all used drugs and diagnost ic
techniques that are widely available. We did not include any HIV-posit ive people in this meta-analysis, so when making
recommendations regarding the use of cort icosteroids in HIV-posit ive people with TB pleurisy, guideline panels may wish to
consider downgrading for indirectness. Only one trial included children aged over 11 years of age (Galarza 1995), but we did
not downgrade as pleural TB is not common in children.
8Two of the six trials reported pulmonary funct ion tests at the end of treatment (Galarza 1995; Wyser 1996), but data were
insuf f icient to combine these outcomes in a meta-analysis. The data are in Table 7, and suggest that in these trials there was
lit t le or no dif ference in mean percentage predicted FVC at the end of treatment. The number of part icipants in each group
with pulmonary funct ion tests suggest ive of a funct ional respiratory impairment are not reported.
9Downgraded by one for risk of bias: there were concerns about randomizat ion method and allocat ion concealment.
Addit ionally, report ing of adverse events varied signif icant ly across the trials, and some trials only reported on adverse events
in the steroid group, and it is likely that some trials did not detect or report all adverse events.
10Downgraded by one for serious imprecision: the CI around the summary ef fect est imate is wide, with a maximum increased
risk of adverse ef fects leading to study drug discont inuat ion of nearly 700% and a minimum increased risk of 12%, which may
not be clinically signif icant when weighed against possible benef its of steroids.
11Downgraded by two for serious imprecision: the CI around the summary ef fect est imate is very wide, and possible ef fects
range f rom large benef its to signif icant harms.
12Downgraded by one for indirectness: only one trial included HIV-posit ive people and assessed HIV-related adverse events
(Elliot t 2004). Part icipants in this trial were not treated with ant iretroviral therapy, which is known to prevent cryptococcal
meningit is in HIV-posit ive people; therefore this est imate may not be applicable to HIV-posit ive people on ant iretroviral
therapy. This trial did not include any children.
13Prevalence of Kaposi’s sarcoma of 1.4% in HIV-posit ive adults on clinic enrolment taken f rom Semeere 2016, a mult i-centre
prospect ive cohort study performed in Uganda and Kenya.
14Downgraded by two for serious imprecision: the CI around the summary ef fect est imate is very wide, and possible ef fects
range f rom large benef its to signif icant harms.
15Downgraded by one for indirectness: only one trial included HIV-posit ive people and assessed HIV-related adverse events
(Elliot t 2004). Part icipants in this trial were not treated with ant iretroviral therapy, which is known to treat and prevent Kaposi’s
sarcoma in HIV-posit ive people, therefore this est imate may not be applicable to HIV-posit ive people on ant iretroviral therapy.
This trial did not include any children.
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B A C K G R O U N D
Tuberculosis (TB) is an infectious disease caused byMycobacterium
tuberculosis complex, and is a major cause of illness and death
worldwide. In 2014 approximately 9.6 million people newly de-
veloped the disease and there were 1.5 million deaths globally
(WHO 2015). TB infects the lungs, and is transmitted by droplet
spread from coughing people with active pulmonary TB, but it
can also spread to other body sites and cause extrapulmonary TB
(EPTB).
Description of the condition
Pleural TB is one of the most common forms of EPTB, with an
incidence of 3% to 25% of people with TB (Light 2010; Sharma
2004). The incidence is higher in high TB prevalence settings
(Jeon 2014). Immune compromise is an important risk factor for
all forms of TB, and evidence suggests that pleural TB is more
common in people living with HIV (Batungwanayo 1993; Frye
1997; Pozniak 1995; Saks 1992). Pleural TB can be a manifesta-
tion of TB disease post-primary infection, or due to reactivation
of latent TB (Light 2010).
Clinically, pleural TB presents as an acute illness consisting of
cough, fever, chest pain, and shortness of breath (Morehead 1998),
and usually a pleural effusion is demonstrated on chest X-ray.
Pleural TB usually resolves without treatment of any kind, but
untreated patients may experience longer duration of the acute
symptoms and risk recurrence of active TB at a later point in time
(Light 2010). Pleural TB can be complicated by massive effusion
leading to respiratory compromise in the short term, and pleural
thickening, fibrosis, and pleural adhesions causing impaired res-
piratory function in the medium- to long-term.
Pleural TB is thought to be caused by a delayed type (type IV)
hypersensitivity reaction following release of mycobacterial anti-
gens into the pleural space (Rossi 1987), as a result of rupture of
a subpleural focus of TB infection in the lung (Stead 1955). This
explains the tendency towards resolution of the effusion and asso-
ciated symptoms with or without treatment of the TB infection,
and the fact that culture of pleural fluid is nearly always negative
for M. tuberculosis. There appears to be a spectrum of disease in
pleural TB in terms of the extent of the underlying lung infection,
which could be important in terms of patient outcomes and the
potential for corticosteroids to be effective (Table 1). A system-
atic review that includes 18 trials and 3816 participants suggests
that corticosteroids probably do not improve mortality rates, spu-
tum smear or culture conversion in people with pulmonary TB
(Critchley 2014). One cohort study of people with pleural TB in
Spain reported evidence of pulmonary TB infection on chest X-
ray in 20% of 254 participants (Valdés 1998). Pulmonary involve-
ment rose to 86% in another cohort where computed tomogra-
phy (CT) scanning was used (Kim 2006). Shu 2011 demonstrated
that pulmonary involvement (as defined by positive sputum cul-
ture and/or chest X-ray appearances) was an important predictor
of mortality in hospitalised pleural TB patients in Korea, and was
associated with a longer hospital stay.
Diagnosis of pleural TB can be challenging with traditional mi-
croscopy and culture methods being relatively insensitive when
used on pleural fluid, and newer modalities such as Xpert®MTB/
RIF have similar limitations (Denkinger 2014). Histopathologi-
cal examination and mycobacterial culture performed on pleural
biopsy samples are regarded as more reliable tests, and yielded a
diagnosis in 227/248 patients (91%) in one cohort study (Valdés
1998).
Description of the intervention
Corticosteroids are hormones produced by the adrenal cortex
which have a variety of physiological functions, including carbo-
hydratemetabolism, protein catabolism, regulation of electrolytes,
the stress response and control of inflammation. Corticosteroids
induce their anti-inflammatory effect through the regulation of
gene expression in cells, leading to increased expression of genes
which inhibit inflammatory pathways, and repression of genes en-
coding pro-inflammatory proteins (Barnes 2006). Multiple syn-
thetic forms of these hormones have been produced and are used
in the treatment of a wide variety of inflammatory conditions.
Prednisolone is a synthetic corticosteroid derived from cortisol,
and prednisone is a pro-drug that is converted into the active form
prednisolone by the liver. Several formulations of each drug are
used for different conditions and diseases; in TB pleurisy patients
are usually offered them in tablet form.
Corticosteroids have been used inmedicine for many decades, and
have well-characterised adverse effect profiles. Adverse effects for
medium to long-term use include hyperglycaemia, hypertension,
increased risk of infection, osteoporosis, gastric ulceration and gas-
trointestinal bleeding, thinning of the skin, proximal myopathy,
psychiatric symptoms, and development of moon face, striae and
acne (Cushing’s syndrome). The use of synthetic corticosteroids
can induce adrenocorticoid insufficiency, and so patients receiv-
ing more than one week’s treatment must have the dose slowly
reduced to avoid acute adrenal insufficiency causing hypotension
and hypoglycaemia which can be life-threatening (BNF 2016).
How the intervention might work
Therapeutic options for pleural space infections include intra-
venous antibiotic administration, chest tube drainage, intrapleural
administration of a fibrinolytic agent to dissolve fibrous adhesions,
thoracotomy to remove fibrinous and infected tissue, and steroid
therapy (Chapman 2004).
The theoretical basis for using corticosteroids is that they sup-
press the delayed type hypersensitivity inflammatory response trig-
gered by the release of tubercular antigens into the pleural space
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which is believed to be responsible for tuberculous pleurisy. One
corticosteroid is prednisone, which is converted in the liver into
the active drug, prednisolone. Prednisolone is recommended at a
daily dose of about 1 mg/kg gradually reducing after one to two
weeks, with a total treatment course sometimes being as long as
three months (Lemaistre 1951; Mathur 1960; Morehead 1998;
Blumberg 2003).
Corticosteroids have anti-inflammatory properties, produced
mainly via suppression of pro-inflammatory gene expression and
activation of anti-inflammatory genes (Barnes 2006). While the
inflammatory response is necessary to control the infection, exces-
sive inflammation can lead to tissue damage and fibrosis, which
could cause long-term morbidity. Suppression of the inflamma-
tory response in pleural TB could reduce the symptoms and signs
associated with the inflammatory process: fever, progression of the
pleural effusion, malaise. Corticosteroids could therefore reduce
the duration or severity of symptoms in the short term, and also
reduce the risk of tissue damage leading to lung impairment in the
long term.
Why it is important to do this review
Studies of adjunctive corticosteroids for the treatment of tuber-
culous pleural effusion show conflicting results. Non-randomized
studies in the pre-HIV era found that corticosteroids led to more
rapid resolution of the effusion and reduced likelihood of resid-
ual pleural thickening and pleural adhesions (Menon 1964; Singh
1965). An observational study of 165 HIV-positive participants
with tuberculous pleural effusion found that prednisolone was as-
sociated with decreasing rates of lymphadenopathy and cough as
well as improved survival (Elliott 1992; Elliott personal commu-
nication).
In contrast, a critical appraisal of published studies demonstrated
beneficial effects of corticosteroids on acute symptoms, but it
found no benefit for chronic endpoints such as fibrosis, irrespec-
tive of dose (Dooley 1997). The authors noted that many of the
studies lacked rigour and clinical correlations. The previous ver-
sion of this Cochrane review (Engel 2007), which included six
trials and 633 participants, concluded that data were insufficient
to support the use of corticosteroids in pleural TB.
In addition to the uncertainty about benefits of corticosteroid ther-
apy, there is concern about potential risks. In immunocompro-
mised patients, such as those infected with HIV, corticosteroids
may further constrain the immune system leading to an increased
frequency of opportunistic infections and tumours such as Ka-
posi’s sarcoma, a vascular tumour accompanied by numerous un-
connected lesions of the skin and associated with human her-
pes virus-8 infection (Ensoli 2001). More generally, adverse ef-
fects of corticosteroids such as fluid retention and gastrointesti-
nal disturbances have also been documented in people with TB
(Anonymous 1983). Other adverse effects associated with corti-
costeroids include high blood pressure, high blood glucose or ex-
acerbation of existing diabetes mellitus, weight gain, increased sus-
ceptibility to infection, gastrointestinal bleeding and in long-term
use osteoporosis and changes to the skin and face.
We updated this review with the aim of adding any new evidence
that may have been published since the previous search in 2007.
For this version, we revised the protocol, and in particular altered
the outcomes of interest. This was informed by discussions with
expert clinicians which took place during the development of a
new guideline on extrapulmonary TB in India, the INDEX-TB
guidelines (INDEX-TB 2016).
O B J E C T I V E S
To evaluate the effects of adding corticosteroids to drug regimens
for tuberculous pleural effusion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
People diagnosed with tuberculous pleurisy by chest x-ray (as de-
fined by trial authors) plus any of the following: pleural biopsy for
histology; staining and microscopy for acid-fast bacilli, or culture
of sputum, or both; pleural fluid; or pleural biopsy.
Types of interventions
Intervention
Any corticosteroid at any dose.
Control
Placebo or no adjunctive treatment.
Both treatment groups should receive the same antituberculous
drug regimen.
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Types of outcome measures
Short term (under six months)
• Time to resolution of clinical symptoms (as defined by the
authors, including fever and pain)
• Time to resolution of pleural effusion
Long term (six months or more)
• Pleural changes at the end of treatment (pleural thickening
and pleural adhesions)
• Change in respiratory function
• Disability (as defined by authors)
• Deaths from any cause
We will also report on other outcomes of resolution as defined by
the author.
Adverse effects
• Corticosteroid-associated adverse effects
• HIV-associated adverse effects
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described inAppendix 1: theCochrane InfectiousDiseases
Group Specialized Register (18 November 2016); the Cochrane
Central Register of Controlled Trials (CENTRAL), published in
the Cochrane Library (18 November 2016); MEDLINE (1966 to
18 November 2016); Embase (1974 to 18 November 2016); and
LILACS (1982 to 18 November 2016). We also searched Current
Controlled Trials (18 November 2016) using ’tuberculosis’ and
’pleur*’ as search terms.
Searching other resources
We performed hand searches of the reference lists of all studies
identified with the above methods.
Data collection and analysis
Selection of studies
The review authors screened the results of the search for poten-
tially relevant studies. We independently applied eligibility criteria
and resolved differences in opinion through discussion. Where the
abstracts were unclear or if there was any other reason for uncer-
tainty, we obtained the full-text article before we made a decision
on study eligibility, and we contacted the study authors where nec-
essary. We consulted translators when abstracts were unavailable
in English. We assessed the full-text articles of potentially rele-
vant studies and included trials that met the inclusion criteria. We
listed studies that did not meet our inclusion criteria and stated
the reason for exclusion in a ’Characteristics of excluded studies’
table. We constructed a PRISMA diagram to illustrate the study
selection process.
Data extraction and management
Two review authors (PD and HR) independently extracted data
from the included trials on participant characteristics, diagnostic
criteria, HIV status, antituberculous drug regimen, corticosteroid
regimen, and outcome measures using a pre-piloted data extrac-
tion form. One review author (JY) extracted data from Bang 1997
and Lee 1999 as both trial reports were in Korean. We resolved
disagreements through discussion and contacted the correspond-
ing trial author in the case of unclear or missing data.
For dichotomous outcomes, we recorded the number of partici-
pants that experienced the event and the number of participants
in each treatment group. For continuous outcomes, we extracted
the arithmetic means and standard deviations for each treatment
group together with the numbers of participants in each group.
Assessment of risk of bias in included studies
Two review authors (PD and HR, or JY and HR) independently
assessed the risk of bias for each included trial using the Cochrane
’Risk of bias’ tool (Higgins 2011). We resolved any differences of
opinion through discussion with reference to the trial reports, and
through discussion with the Cochrane Infectious Diseases Group
Co-ordinating Editor, Paul Garner. We followed the guidance to
assess whether adequate steps had been taken to reduce the risk of
bias across six domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessors
• Incomplete outcome data
• Selective reporting
• Other bias
When assessing risk of bias related to blinding (performance bias
or detection bias), we planned to consider the implications of
blinding separately for each outcome, as appropriate.
For assessment of bias related to incomplete outcome data (attri-
tion bias), we used the following criteria to assess risk of bias.
• Low risk: less than 5% of participants were lost to follow-up
• Unclear risk: between 5 and 10% of participants were lost
to follow-up
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• High risk: more than 10% of participants were lost to
follow-up
For selective reporting (reporting bias), we used the following cri-
teria to determine the risk of bias.
• Low risk: the trial authors stated in the introduction or
method sections the outcomes they would look at, and they
reported all of them in the results section
• Unclear risk: the trial authors did not state in the
introduction or method sections the outcomes they would look
at
• High risk: the trial authors stated the outcomes they would
look at but they did not report all of them in the results section
We categorized these judgments as either at low, high, or unclear
risk of bias. We attempted to contact the trial authors for clarifica-
tion if any details were unclear; where our judgement is recorded
as ’unclear’ we were unable to amend our judgement after we con-
tacted the trial authors. The results of the ’Risk of bias’ assessment
are displayed in the ’Characteristics of included studies’ tables.
Measures of treatment effect
For dichotomous outcomes, we used relative risk as themeasure of
treatment effect for analysis. For continuous outcomes we planned
to use mean difference, but this was not necessary in the final
review draft.
Unit of analysis issues
There were no cluster-RCTs amongst the included trials, so indi-
vidual participants were the unit of analysis.
Dealing with missing data
The primary analysis was an intention-to-treat analysis where all
participants randomized to treatment were included in the de-
nominator, where possible. This analysis assumes that all losses to
follow-up have good outcomes. We planned to explore the effect
of losses to follow-up on the overall effect estimates by performing
sensitivity analyses.
Assessment of heterogeneity
We assessed heterogeneity by visually inspecting the forest plots to
determine closeness of point estimates with each other and overlap
of confidence intervals (CIs). We used the Chi² test with a P value
of 0.10 to indicate statistical significance, and the I² statistic to
assess heterogeneitywith a value of 50%taken to indicate statistical
heterogeneity. We planned to investigate heterogeneity through
the following subgroup analyses: corticosteroid dose, HIV status,
and methodological quality.
Assessment of reporting biases
We planned to look for publication bias by constructing a funnel
plot, but there were too few studies to do this.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 5)
(Review Manager 5). For outcomes where it was possible to com-
bine data and clinical heterogeneity was low, we decided to per-
form a meta-analysis. We used risk ratios (RR) with 95% CIs and
the fixed-effect model. For outcomes where it was not possible to
combine data, we described the results in tables. We summarized
the adverse event data in tables and performed meta-analysis for
adverse events leading to discontinuation of the trial drug, and
HIV-associated adverse events.
Subgroup analysis and investigation of heterogeneity
Where there was substantial unexplained statistical heterogeneity,
we carried out subgroup analyses to investigate possible causes.
Sensitivity analysis
To explore the possible effect of losses to follow-up, we planned
to conduct a worst case scenario analysis and compare it with an
available-case analysis for the outcome pleural changes at the end
of treatment. There were few losses to follow-up in the included
trials, and the two trials with the highest number of losses to
follow-up did not state which treatment groups these participants
were randomized to. Therefore we did not conduct the sensitivity
analysis as planned.
Quality of the evidence
We assessed the quality of the evidence using the GRADE ap-
proach (Jüni 2001).WeusedGRADEproGuidelineDevelopment
Tool (GDT) software to construct a ’Summary of findings’ table
(GRADEpro GDT 2014).
R E S U L T S
Description of studies
Results of the search
In the 2007 version of this Cochrane Review, we screened 48
studies, of which we identified 27 published trials for possible
inclusion into the review. Six trialsmet the inclusion criteria (Engel
2007). In this review update, the search returned one new study,
which we excluded. Figure 1 shows the study selection process.
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We have described the characteristics of the included studies in
the ’Characteristics of included studies’ tables and summarized the
results in Table 2.
Figure 1. Study flow diagram.
Included studies
Settings
The six trials included 633 participants, with a range of 45 to 197
per trial, and were conducted in a various countries: Taiwan (Lee
1988), Spain (Galarza 1995), South Africa (Wyser 1996), Korea
(Bang 1997; Lee 1999), and Uganda (Elliott 2004). All trials were
single centre trials based in large tertiary care hospitals.
Participants
All participants were adults except in one trial, Galarza 1995,
which included people aged 11 years and older. All trials included
participants of both sexes; overall 59% were male, with a range of
51% to 64% across trials.
One trial included only HIV-positive participants (Elliott 2004),
two trials excluded HIV-positive participants (Galarza 1995;
Wyser 1996), while the other included trials did not mention the
HIV status of the participants.
All but one trial, Galarza 1995, specified the exclusion of partici-
pants with co-morbidities that may be exacerbated by the use of
corticosteroids, particularly hypertension, diabetes mellitus, and
peptic ulcer disease. Elliott 2004 also specified the exclusion of
participants with another major HIV-related disease.
We have described the diagnostic tests performed in each included
trial in Table 3. Diagnosis of pleural TB was made on the basis of
either characteristic histopathological features on pleural biopsy
or positive culture or acid-fast bacilli (AFB) on smear microscopy
staining frompleural fluid, biopsy or sputum in three trials (Elliott
2004; Lee 1999; Wyser 1996). Galarza 1995 also included partic-
ipants with a diagnosis of tuberculous pleurisy based on a com-
bination of at least two of: reactive Mantoux test, lymphocytic
pleural fluid, and raised adenosine deaminase activity in pleural
fluid. Bang 1997 only included participants who had positive mi-
croscopy for AFB from sputum, pleural fluid, or pleural biopsy.
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Lee 1988 included participants with pleural biopsy “reported as
pleural tuberculosis or chronic granulomatous inflammation”.
Interventions
Wehave summarized the antituberculous therapy (ATT) regimens
used in the included trials in Table 2, and the corticosteroid regi-
mens used in Table 4.
Four trials compared either prednisone or prednisolone with
placebo as an adjunct to an established antituberculous regimen
containing at least isoniazid and rifampicin (Elliott 2004; Galarza
1995; Lee 1988; Wyser 1996). Bang 1997 and Lee 1999 did not
use any comparative treatment in the control group.
Four trials used weight-based dosing of corticosteroids; Bang 1997
started at 1.0 mg/kg twice daily, Galarza 1995 started at 1.0 mg/
kg/day, and Lee 1988 and Wyser 1996 started at 0.75 mg/kg/
day. Elliott 2004 started at 50 mg/day for all participants, and Lee
1999 started at 30 mg four times daily. Lee 1988 and Wyser 1996
tapered the dose of corticosteroid according to the participant’s
clinical progress; the other included trials either had fixed tapering
regimens or did not describe the tapering regimen.
All included trials described performing diagnostic pleural aspira-
tion (thoracocentesis) as part of eligibility screening and diagnosis
of pleural TB. Two trials also performed therapeutic thoracocen-
tesis (Galarza 1995; Wyser 1996). In Galarza 1995, pleural fluid
was drained in all participants before discharge “until a third of the
hemithorax was observed to be occupied in a standard chest ra-
diograph”. In Wyser 1996, thoracoscopy and bronchoscopy were
performed in all participants under general anaesthesia at admis-
sion, and chest drains were left in situ for 48 hours following the
procedure to drain remaining pleural fluid.
Outcomes
Follow-up varied from six months to 24 months. Two trials did
not clearly state the length of follow-up (Bang 1997; Lee 1999).
None of the included trials reported all the outcome measures
chosen for this review.
Five trials reported on resolution or improvement of clinical symp-
toms in some way. Bang 1997 and Wyser 1996 both used self-re-
ported questionnaires to assess the time until symptom improve-
ment and resolution in all participants; Wyser 1996 asked partici-
pants to grade the severity of a range of symptoms on a visual ana-
logue scale. Lee 1988 reported the time to resolution of symptoms
“including fever, chest pain and dyspnoea” for all participants, but
did not specify how this was assessed. Elliott 2004 reported on
improvement of anorexia, weight loss, and cough, but data for
other symptoms was not reported. Galarza 1995 reported on time
to resolution of fever.
Five trials reported on time to resolution of pleural effusion (Bang
1997; Elliott 2004;Galarza 1995; Lee 1988; Lee 1999). Four trials
reported the number of participants with residual pleural effusion
at various time points during treatment (Bang 1997; Elliott 2004;
Lee 1988; Lee 1999). Bang 1997 and Lee 1988 also reported the
mean number of days to resolution of pleural effusion. Galarza
1995 reported the mean reabsorption index for all participants
over time. The trial authors calculated the reabsorption index as
follows: (length of affected hemithorax/length of healthy hemitho-
rax) x 100. Wyser 1996 reported recurrence of pleural effusion,
rather than time to resolution, as all participants had therapeutic
thoracocentesis at the start of treatment.
Five trials reported on pleural changes at various time points
throughout treatment and at the end of follow-up (Bang 1997;
Galarza 1995; Lee 1988; Lee 1999; Wyser 1996). Galarza 1995
andWyser 1996 described the diagnostic criteria for pleural thick-
ening on chest X-ray (Wyser 1996 also used high-resolution com-
puted tomography). Three trials did not describe the criteria
for classifying participants as having pleural adhesions or pleural
thickening (Bang 1997; Lee 1988; Lee 1999).
Two trials reported on respiratory function (Galarza 1995; Wyser
1996). In Wyser 1996, spirometry and body plethysmography
were performed at admission and at various points during follow-
up. In Galarza 1995, spirometry was performed at the start and
end of treatment. Neither trial reported the complete data for this
outcome.
Disability was not reported in any of the included trials. Only one
trial reported any deaths (Elliott 2004).
Elliott 2004 reported on CD4+ cell count at enrolment to the trial
and at 1, 2, 6, and 18 months after start of treatment. A subset of
participants (N = 40) also had blood and pleural fluid specimens
analysed for HIV viral load.
All trials reported adverse events, although there was variation in
the level of detail. Elliott 2004 reported on HIV-related disease as
well as corticosteroid-related adverse events.
Excluded studies
We have listed the reasons for excluding 22 studies in the
’Characteristics of excluded studies’ section.
Risk of bias in included studies
See the ’Characteristics of included studies’ tables for details of in-
dividual included trials. The results of the ’Risk of bias’ assessment
are summarized in Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included trials.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial.
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Allocation
All included trials were reported as randomized. Elliott 2004 ex-
plicitly stated that random numbers were computer-generated,
which we considered to be low risk of bias. The other included
trials did not indicate how the sequence was generated, and we
assessed them as at unclear risk of bias.
One trial gave a detailed description of the method of allocation
concealment and we assessed it as at low risk of bias; briefly, pred-
nisolone and matching placebo tablets were packaged in identical
sequentially numbered plastic bags labelled with the randomiza-
tion code by two people unrelated to the trial (Elliott 2004). The
rest did not describe the method of allocation concealment, and
so we classified them as at unclear risk of bias.
Blinding
Four trials described blinding of participants and personnel and
we assessed them as at low risk of bias (Elliott 2004; Galarza 1995;
Lee 1988;Wyser 1996). Bang 1997 andLee 1999 did notmention
blinding, and therefore we classified them as at unclear risk of bias.
Two trials specified blinding of outcome assessors and we assessed
them as being at low risk of bias (Elliott 2004;Wyser 1996). None
of the other trials reported whether or not outcome assessors were
blinded to treatment allocation, and so we assessed them as at
unclear risk of bias.
Incomplete outcome data
Three trials did not report any losses to follow-up (Bang 1997;
Galarza 1995; Lee 1999). Bang 1997 excluded one participant in
the corticosteroid group from the analysis as the trial drug had
to be stopped due to epigastric pain. Elliott 2004 reported 3/197
(1.5%) participants lost to follow-up; one from the placebo group
and two from the corticosteroid group. We categorised these trials
as at low risk for attrition bias.
Wyser 1996 excluded 4/74 (5.4%) from the analysis; three due
to noncompliance with treatment and one due to a diagnosis of
oesophageal cancer during treatment. The authors do not report
which groups the excluded participants were allocated to. We cat-
egorised this trial as at unclear risk of attrition bias.
Lee 1988 excluded 5/45 (11.1%) from the analysis; one due to a
diagnosis of renal cell carcinoma during treatment, and four were
lost to follow-up. We classified this trial as at high risk of attrition
bias.
Selective reporting
Trial protocols were unavailable for all of the included trials. Five
trials stated the outcomes clearly in the introduction and methods
sections of the study reports, and reported all stated outcomes
(Bang 1997; Galarza 1995; Lee 1988; Lee 1999; Wyser 1996).
Elliott 2004 reported that the hypothesis of the trial was that pred-
nisolone would improve long-term survival, and decrease HIV vi-
ral replication, but did not list the planned outcomes. We assessed
this trial as at high risk of reporting bias because in the results
section it implied that data on resolution of symptoms that did
not demonstrate a statistically significant positive effect of pred-
nisolone was not reported, whereas data were reported for the out-
comes of anorexia, weight, and cough where a statistically signifi-
cant positive effect was found.
Other potential sources of bias
We did not find enough trials that met the inclusion criteria for
us to conduct a funnel plot to look for possible publication bias.
Effects of interventions
See: Summary of findings for the main comparison
Time to resolution of clinical symptoms
Due to the different units of measurement used in the trials, and
insufficient reported data, it was not possible to combine the effects
in a meta-analysis for this outcome. We have presented the results
from the included trials in Table 5. Qualitatively, corticosteroids
appear to be associated with more rapid resolution of symptoms,
but we were unable to assess the relative effect of corticosteroids
statistically.
Time to resolution of pleural effusion
Five trials reported on time to resolution of pleural effusion (
Bang 1997; Elliott 2004; Galarza 1995; Lee 1988; Lee 1999).
We combined data for the number of participants with a residual
pleural effusion on chest X-ray in each treatment group from four
trials. Bang 1997, Elliott 2004, and Lee 1988 reported data across
three time points (4 weeks, 8 weeks, and 24 weeks), and Lee 1999
reported data for two time points (8 weeks and 24 weeks). Galarza
1995 presented the mean reabsorption index for each treatment
group at four weeks, and so we could not use data from this trial in
the meta-analysis. We have presented the results from each trial in
Table 6. Wyser 1996 reported on recurrence of pleural effusion, as
all participants had drainage of their pleural effusions at admission
to the trial, and reported no recurrences of pleural effusion in
either group.
The initial meta-analysis, which includes data from Bang 1997,
Elliott 2004, Lee 1988, and Lee 1999, found substantial statistical
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heterogeneity at all three time points, and we conducted a sub-
group analysis to explore this (Analysis 2.1; Analysis 2.2). When
we excluded trials that were at high risk of bias for selection bias
(randomization and allocation concealment) from the meta-anal-
ysis, the statistical heterogeneity resolved. In these two trials it is
possible that the trial investigators allocated a greater proportion
of participants with more severe pleural effusions to the corticos-
teroid group, believing that corticosteroids would be of benefit to
them (Bang 1997; Lee 1999). This would lead to bias towards the
null, and a misleading summary effects estimate. For this reason,
we excluded the trials that were at high risk of selection bias from
the meta-analysis.
The results showed a reduction in the risk of having residual pleural
fluid on chest X-ray at all three time points in participants treated
with corticosteroids: by 36% at four weeks (RR 0.64, 95% CI
0.49 to 0.84; 237 participants, 2 trials), 45% at eight weeks (RR
0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials), and 65%
at 24 weeks (RR 0.35, 95% CI 0.18 to 0.66; 237 participants, 2
trials).
Pleural changes on chest X-ray at the end of
treatment
Five trials reported on chest X-ray changes to the pleura at the
end of treatment (Bang 1997; Galarza 1995; Lee 1988; Lee 1999;
Wyser 1996). The terms ’pleural thickening’ and ’pleural adhe-
sions’ were used to describe these changes, and in some cases
seemed to be used interchangeably. We found that corticosteroids
may reduce the risk of having pleural changes on chest X-ray after
at least six months by 28% (RR 0.72, 95% CI 0.57 to 0.92; 393
participants, 5 trials, low certainty evidence; Analysis 1.2).
One trial, Galarza 1995, attempted to quantify the degree of pleu-
ral thickening by measuring the maximal pleural thickening in
millimetres at 1, 6, and 12 months after enrolment, and reported
themeanmaximal pleural thickness for each treatment group. The
prednisolone group had a mean maximal pleural thickness of 1.77
mm (range 0 to 40 mm), and for the placebo group 2.23 mm (0
to 15 mm), with a P value of more than 0.05.
Wyser 1996 also performed high resolution CT scan of the chest
in most participants, and found 17/32 participants in the pred-
nisolone group and 21/35 participants in the placebo group had
pleural thickening at the end of treatment using this test (P =
0.52).
None of the included trials looked at the extent of pleural changes
on chest X-ray in terms of area of pleural change.
Change in respiratory function
Two trials with 191 participants measured improvement in res-
piratory function and found no difference between the groups
(Galarza 1995; Wyser 1996). We have summarized the results in
Table 7.
In Galarza 1995, mean forced vital capacity (FVC) was 95% in
both the treatment and control groups at the end of treatment;
in Wyser 1996 it was 85% in the corticosteroids group and 80%
in the placebo group (P = 0.65). We could not perform a meta-
analysis due to insufficient reported data.
Disability
None of the included trials looked at disability or functional im-
pairment after treatment for TB pleurisy.
Death from any cause
Only Elliott 2004 reported any deaths, with 36/99 deaths in the
prednisolone group, and 39/98 deaths in the placebo group,mean-
ing the relative risk of death in the prednisolone group was 0.91
(95% CI 0.64 to 1.31; 197 participants, 1 trial; Analysis 1.3),
which indicated that prednisolone did not confer a survival bene-
fit. The trial authors commented that mortality rates were higher
in participants with low CD4+ cell counts on enrolment to the
trial.
Adverse effects of treatment
More participants in the corticosteroid group had adverse events
leading to discontinuation of the study drug (RR 2.78, 95% CI
1.11 to 6.94; 590 participants, 6 trials, low certainty evidence; Anal-
ysis 1.4). We have summarized the results in Table 8.
There was variation in the level of detail reported across the differ-
ent trials, and assessment of participants to detect adverse effects
of treatment also varied.
Bang 1997 reported one participant from the corticosteroid group
was withdrawn from the study due to aggravation of epigastric
pain.
Lee 1988 reported one participant from the corticosteroid group
developed moon-shaped face, epigastric pain, and lower limb
oedema which resolved on tapering the study drug.
Wyser 1996 reported that the only adverse effect observed was epi-
gastric pain, which affected 4/34 participants in the corticosteroid
group and 3/36 participants in the placebo group.
Elliott 2004 reported 9/99 participants in the corticosteroid group
stopped the trial drug due to hyperglycaemia (two participants),
hypertension (three participants), herpes zoster (three partici-
pants), or oesophageal candidiasis (one participant). In the placebo
group 2/98 participants stopped the trial drug; one participant
due to hyperglycaemia and one participant due to hypertension.
Galarza 1995 reported no adverse events in either treatment group,
and Lee 1999 reported no significant adverse events in the partic-
ipants treated with steroids.
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HIV-associated adverse events
Only Elliott 2004 included HIV-positive participants. The trial
reported adverse events related to HIV, including candidiasis, her-
pes simplex and herpes zoster, cryptococcal meningitis, gastroen-
teritis, and Kaposi’s sarcoma (summarized in Table 9). For most
of these adverse events there was no difference between the corti-
costeroid and placebo groups. For Kaposi’s sarcoma, there was a
statistically non-significant trend towards increased risk with cor-
ticosteroids: 6/99 in the corticosteroid group developed Kaposi’s
sarcoma compared with 0/98 in the placebo group (RR 12.87,
95%CI 0.73 to 225.40; 197 participants, 1 trial, very low certainty
evidence).
D I S C U S S I O N
Summary of main results
See ’Summary of findings’ table 1 (Summary of findings for the
main comparison).
Six trials met the inclusion criteria; we have not included any
new trials since the 2007 version of this Cochrane Review (Engel
2007), and we did not find any trials in progress that address this
question.
There was a trend towards faster resolution of symptoms, such
as fever and chest pain, with corticosteroids across all included
trials, but the trials reported insufficient data to produce a meta-
analysis addressing time to resolution of symptoms, and there were
variations across studies in terms ofwhich symptomswere reported
and who the participants were monitored and assessed.
Corticosteroids probably reduce the time to resolution of pleural
effusion.
Corticosteroids may reduce risk of pleural changes on chest X-
ray at the end of treatment by 28% (RR 0.72, 95% CI 0.57 to
0.92; 393 participants, 5 trials, low certainty evidence). On average,
half the participants in the control group had pleural changes at
the end of at least six months, giving an estimated absolute risk
reduction of 14% with corticosteroids.
There was insufficient data to draw conclusions about the effect of
corticosteroids on respiratory function after treatment, and none
of the included trials reported on disability after treatment. Only
one trial reported on death (Elliott 2004), and the trial authors’
analysis suggests that death was related to low CD4+ cell counts,
which implied that death was related to severity of HIV disease.
Corticosteroids had no effect on all-cause mortality in this trial
(RR 0.91, 95% CI 0.64 to 1.31; 197 participants, 1 trial).
Corticosteroids may increase risk of adverse events leading to dis-
continuation of the study drug (RR 2.78, 95% CI 1.11 to 6.94;
587 participants, 6 trials, low certainty evidence). Commonly re-
ported adverse effects included epigastric pain, hypertension, and
hyperglycaemia.
Only one trial included HIV-positive people and reported on
HIV-associated adverse events (Elliott 2004). While there was
no significant difference between the corticosteroid and placebo
groups for any of the conditions observed, Kaposi’s sarcoma was
only observed in the group receiving steroids: 6/99 in the corti-
costeroid group developed Kaposi’s sarcoma compared with 0/98
in the placebo group (RR 12.87, 95% CI 0.73 to 225.40; 197
participants, 1 trial, very low certainty evidence).
Overall completeness and applicability of
evidence
The six trials included male and female participants, who were
mostly HIV-negative adults. One trial included children over the
age of 11 years (Galarza 1995), and one trial included only HIV-
positive adults (Elliott 2004). The trials reflected the fact that
pleural TB is more common in adults, but HIV-positive people
are under-represented in this review, and the results of the pooled
estimates may be less applicable to HIV-positive people. The in-
cluded trials were all conducted in tertiary hospital settings, in a
countries varying from low to high TB burden and HIV preva-
lence.
The method of diagnosis of pleural TB varied between the in-
cluded trials (see Table 3), but were representative of diagnostic
tests commonly available in high- and middle-income settings.
Culture and histopathology are less accessible in low-income set-
tings, where diagnosis may be based on clinical presentation and
X-ray findings alone.
The antituberculous treatment (ATT) that participants received
varied across the included trials, and in some trials the treatment
given was significantly different from widely recommended first-
line treatment for drug-sensitive TB (see Table 2). Most notably,
the older trials included either two drugs (Lee 1988), or three
drugs (Galarza 1995; Wyser 1996), in their regimens rather than
all four currently recommended first-line drugs in the intensive
phase of treatment. Participants were given at least six months of
ATT in all trials. This variation in ATT was not associated with
statistically significant heterogeneity in any of our analyses. As the
more recent trials used regimens that are the same or very similar
to currently recommended regimens for drug-sensitive TB, it is
unlikely that the variation in ATT regimens between the trials
limits the applicability of the evidence.
For some outcomes, such as respiratory function and time to reso-
lution of symptoms, incomplete reporting of data and differences
in units meant that we could not combine data to generate a sum-
mary effects estimate.
Quality of the evidence
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We assessed the quality of the evidence using the GRADE ap-
proach (Jüni 2001), and reported the outcomes in a ’Summary of
findings’ table (Summary of findings for the main comparison).
For time to resolution of pleural effusion, we combined data on
residual pleural fluid on chest X-ray from four trials. As described
in the results section, after exploring high unexplained statistical
heterogeneity for this outcome, we chose to exclude the two trials
that were at high risk of selection bias from the final analysis to
avoid a misleading summary estimate of effect. The exclusion of
studies from the meta analysis generates uncertainty, and therefore
we chose to downgrade by one because of this.We also downgraded
for imprecision; the number of participants and events is small,
the meta analysis is probably underpowered.
We graded the summary effects estimate for pleural changes at
the end of treatment as low certainty evidence, and downgraded
due to concerns about risk of bias relating to randomization and
allocation methods, and for imprecision relating to the relatively
small number of events and participants.
For long-term functional respiratory impairment, we graded the
quality of the evidence as very low. Meta-analysis was not possible
for this outcome due to insufficient reporting of data, and we
reported the available data in Table 7. Although two trials reported
the mean percentage predicted forced vital capacity (FVC) at the
end of treatment (Galarza 1995, Wyser 1996), neither the results
per participant nor the variance were reported.
For adverse events leading to discontinuation of the trial drug, we
assessed the quality of the evidence as low. We downgraded for
risk of bias relating to randomization and allocation concealment,
and also reporting as some trials did not report on adverse events
in detail. Also a few only referred to adverse effects associated with
steroids in the steroid group, which raised the concern that adverse
events in the control group were not detected or reported.
For adverse events relating to HIV, we graded the estimates of
effect relating to two serious, life-threatening HIV-related diseases
- cryptococcal meningitis and Kaposi’s sarcoma - and judged the
quality of the evidence to be very low. We downgraded by two for
imprecision caused by the small number of events andparticipants,
and also by one for indirectness as the participants were all from
one single-centre trial and none were on antiretroviral therapy.
These estimates of effect may not be applicable to HIV-positive
people in other settings or those taking antiretroviral therapy.
Potential biases in the review process
We attempted to limit bias in the review process. Vittoria Lutje, the
Cochrane Infectious Diseases Group Information Specialist, con-
ducted the literature searches, and it is unlikely that these searches
missed any major trials; however, we cannot rule out the possibil-
ity that we missed some small unpublished trials. The funnel plot
did not assist with this because there were too few included trials.
To limit bias in the trial selection process and data extraction, we
independently examined the search results, determined study se-
lection, and extracted data.
Agreements and disagreements with other
studies or reviews
There are relatively few studies and reviews on this topic in the lit-
erature.We could find no other systematic reviews that address this
question. Chapman 2004, a narrative review of the diagnosis and
management of pleural space infection, comments that the role of
steroids is uncertain as study findings are conflicting, and do not
provide information about the effect of steroids on long-term lung
function and mortality. Another narrative review, Ferreiro 2014,
drew similar conclusions, and noted that the conflicting results
between studies and the possibility raised by Elliott 2004 that use
of corticosteroids in HIV-positive patients with TB pleurisy may
lead to increased risk of Kaposi’s sarcoma. Kadhiravan 2010 com-
mented on the previous version of this review (Engel 2007), and
noted that while there appears to be an effect of corticosteroids on
pleural thickening, the available evidence does not show an effect
on lung function.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The included trials in this review do not provide substantive evi-
dence on patient-important outcomes to guide recommendations
on the use of corticosteroids in people with TB pleurisy. The effi-
cacy of corticosteroids in reducing the time to resolution of pleural
effusion or symptoms is uncertain, although the included trials
that were at low risk of bias did demonstrate more rapid resolution
of pleural effusion on chest X-ray in participants treated with cor-
ticosteroids. There may be a decreased risk of pleural changes such
as pleural thickening and pleural adhesions on chest X-ray at the
end of treatment with corticosteroids, but it is unclear how this re-
lates to patient-important outcomes such as disability, lung func-
tion, and mortality. The concerns raised regarding adverse events
in both HIV-negative and HIV-positive people with pleural TB
need to be taken into account when deciding whether or not to
use corticosteroids.
Current guidelines for TB treatment do not recommend the use
of corticosteroids in pleural TB (INDEX-TB 2016; NICE 2016;
WHO 2010).
Implications for research
The literature search performed for this update revealed no new
trials that compared corticosteroids to placebo in people with pleu-
ral TB, and no trials are ongoing at the time of publication of this
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CochraneReview.Weprepared a rapid update of this review as part
of the development process of guidelines on extrapulmonary TB
in India, the INDEX-TB Guidelines (INDEX-TB 2016). During
discussions regarding the use of corticosteroids for pleural TB, the
guideline panel noted that, as pleural TB is generally associated
with low mortality, the priority outcome for consideration is lung
function. The panel felt that the main outcomes in the available
studies are at best proxy measures for lung function, and, given the
evidence for adverse effects of corticosteroids, made a conditional
recommendation against their use in pleural TB.
It is notable that the two trials included in this review that do
report on lung function suggest that, while there was no qualitative
difference between the two treatment groups, many people who
have been successfully treated for pleural TB have poorer than
expected lung function. There are still questions to be answered
regarding lung function, disability, and mortality after pleural TB.
A systematic review of studies that investigated the prevalence
of chronic lung disease in general populations concluded that
pulmonary TB is strongly associated with chronic lung disease,
including chronic obstructive pulmonary disease (COPD) and
bronchiectasis (Byrne 2015). Two studies included in the review
showed a stronger association between pulmonary TB and chronic
lung disease in non-smokers than in smokers, which suggested
that the relationship is not due to confounding risk factors alone.
Indeed, the association between pulmonary TB and chronic lung
disease has been recognized for many decades. More recently the
interconnected causal relationships between TB, HIV, smoking,
and chronic lung disease have been further elucidated, although
many questions regarding pathophysiology remain unanswered
(van Zyl Smit 2010). There is less evidence regarding the asso-
ciation between pleural TB and chronic lung disease or respira-
tory impairment. Candela 2003 reported on functional sequelae
in terms of pulmonary function testing in a cohort of 81 Span-
ish adults with pleural TB with a median follow-up time of 23
months after diagnosis. Investigators found that 8/81 (10%) of
the participants had a restrictive ventilatory deficit (one or both
of FVC and TLC < 80% of predicted, with a FEV1/FVC ratio >
80% of predicted) at the end of follow-up, which they describe as
mild to moderate in all but two cases who were both smokers with
a pre-existing diagnosis of COPD. They found no statistically sig-
nificant association between residual pleural thickening on chest
X-ray and functional sequelae at end of follow-up, although the
sample was too small to rule out an association. They also found
that the pleural fluid profile of participants that went on to have a
restrictive ventilatory deficit demonstrated lower levels of lactate
dehydrogenase and higher lymphocyte count, suggesting a differ-
ence in the inflammatory response in the pleural space. Their re-
sults provide context to the results of this review: if there is poor
correlation between pleural thickening on chest X-ray and func-
tional sequelae, we cannot conclude that if corticosteroids reduce
pleural thickening they are likely to be of benefit in terms reducing
rates of lung function impairment.
Given the uncertainties that exist, further research is warranted to
explore the relevance of discriminating between people presenting
with isolated pleural TB and pleuro-pulmonary TB, using dif-
ferent imaging modalities such as computed tomography and ul-
trasound. Cohort studies are needed in people who have pleural
TB of either type to assess the incidence of functional sequelae,
as measured using spirometry and also disability metrics validated
for disability related to impaired lung function. The utility of fur-
ther randomized controlled trials for corticosteroids in pleural TB
would be informed by the results of such research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bang 1997
Methods Setting: Inha University Hospital, South Korea
Date: recruitment from June 1991 to September 1994
Trial design: prospective randomized study
Follow-up: duration not clearly reported, 8 to 9 months. Chest X-rays were performed
weekly while participants were hospitalized, then monthly after discharge. Participants
were asked to complete a questionnaire detailing their symptoms every day until resolu-
tion of all symptoms
Participants Number of participants: 84 adults (83 included in analysis, 1 participant was excluded
because they experienced increased epigastric pain after commencing steroids and so
study drug was stopped); 49 male (59%), 34 female (41%)
Age: mean 34 years, range 18 to 50 years
Inclusion criteria: patients who were admitted to the hospital and diagnosed with
tuberculous pleurisy. All participants had pleural biopsy and diagnostic pleurocentesis
performed on the 1st or 2nd day of admission. Diagnosis of tuberculosis (TB) pleurisy
was based upon the following: histological findings corresponding to TB on pleural
biopsy, acid-fast bacilli (AFB) positive on smear microscopy or culture positive from
sputum, pleural fluid, or pleural biopsy
Exclusion criteria
• People with pleural effusion caused by congestive heart failure, pneumonia, or
malignancy
• People with diabetes, hypertension, and peptic ulcer disease who could not be
treated with corticosteroids
HIV status: all participants were HIV-negative. The trial took place during a period
when HIV infection was very uncommon in South Korea
Interventions Intervention: ATT plus prednisolone 1 mg/kg twice daily, tapered by 10 mg each week
until complete cessation
Control: ATT alone
ATT: isoniazid (400 mg/day), rifampicin (600 mg/day; 450 mg if weight 50 kg or less),
pyrazinamide (1500 mg/day), ethambutol (800 mg/day) for 2 months followed by same
regimen minus pyrazinamide for 7 months
Outcomes • Mean duration to relief from symptoms, as assessed by a self-reporting
questionnaire asking about presence or absence of sensation of fever, chest pain, cough,
sputum production, shortness of breath, night sweats, weight loss, and fatigue
• Rate of reabsorption of pleural fluid
• Pleural adhesions and thickening
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Bang 1997 (Continued)
Random sequence generation (selection
bias)
High risk The trial authors did not state the method
of randomization, and the number of par-
ticipants in each group appears imbalanced
(steroid group N = 34, control group N =
50)
“Patients deemed eligible for this study
were randomized to the steroid group and
the non-steroid group.”
Allocation concealment (selection bias) Unclear risk The trial authors did not report this infor-
mation.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial authors did not report this infor-
mation.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial authors did not report this infor-
mation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up were reported.
Selective reporting (reporting bias) Low risk The trial protocol was unavailable, but the
trial authors reported all outcomes specified
in the introduction in the results
Other bias Low risk We did not identify any other sources of
bias.
Elliott 2004
Methods Setting: National TB Treatment centre, Mulago Hospital, Kampala, Uganda
Date: recruitment from November 1998 to January 2002
Trial design: randomized, doubled-blind, placebo-controlled trial
Follow-up: all participants were followed up until July 2002; median follow-up time
was 1.48 years in the steroid group, and 1.65 years in the placebo group. Participants
were managed in hospital or as daily ward attenders for the first week of treatment, and
after that were discharged home and visited regularly to monitor treatment for 8 weeks.
Participants then attended clinic monthly until the end of ATT, and then 3-monthly
after ATT completion
Participants Number of participants (% female): 197, 83 (42%) female. 98 received placebo and
99 received prednisolone. Three participants were lost to follow-up and excluded from
the analysis (1 from placebo group, 2 from prednisolone group)
Age: mean 34 years
Inclusion criteria: participants were eligible for screening if theywere > 18 years old with
clinical features consistent with pleural TB and a pleural effusion occupying at least 1/3
of 1 hemithorax on chest X-ray. Screening procedures consisted of medical examination;
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Elliott 2004 (Continued)
blood samples including glucose, HIV, and cryptococcal antigen tests; urine sample for
dipstick; diagnostic pleural aspiration, and pleural biopsy if possible. Pleural TB was
considered to be confirmed if a patient had a positive culture for M. tuberculosis from
pleural biopsy, pleural fluid, or sputum or if histopathological analysis of pleural tissue
was consistent with tuberculous pleurisy
Exclusion criteria: people recently treated with glucocorticoids, pregnant, or breast-
feeding women, and people not resident in Kampala were excluded from screening. The
trial excluded people after screening if they failed to completed the screening procedures,
pleural fluid could not be obtained, they had empyema, they had a second major HIV-
related disease, they had risk factors for serious steroid-related adverse events (history of
diabetes or finding of glycosuria, history or finding of hypertension, history of peptic
ulcer disease, or mental illness), they could not receive standard doses of antituberculous
treatment (ATT) (for example, concurrent liver disease), they were HIV-negative
HIV status: the trial excluded HIV-negative people
Interventions Intervention: ATT plus prednisolone 50 mg daily for 2 weeks, then 40 mg daily for 2
weeks, then 25 mg daily for 2 weeks, then 15 mg daily for 2 weeks, then stopped
Control:ATT plus placebo. ATT: daily rifampicin, isoniazid, pyrazinamide, and etham-
butol for 2 months, followed by daily rifampicin and isoniazid for 4 months; doses ad-
justed for weight using standard criteria
Outcomes • All-cause mortality
• Time to resolution of anorexia, cough, and pleural effusion
• Weight
• CD4 count and viral load
• Adverse events related to steroid use
• Adverse events related to HIV
Notes The trial authors did not mention antiretroviral therapy in this trial. We contacted the
trial authors to check whether any of the participants were given antiretroviral therapy,
and they reported that to the best of their knowledge none of the participants were taking
antiretroviral therapy at any time during the trial
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated by a statistician who was not involved
in the care of the patients, by use of STATA
(version 5; Stata Corporation). Random-
ization was done in blocks of 20.”
Allocation concealment (selection bias) Low risk “Prednisolone and matching
placebo tablets were packaged in identical
plastic bags, which were labeled with ran-
domization code numbers by two people
who were not involved in the study. Medi-
cal staff gave participants the next number
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Elliott 2004 (Continued)
in the sequence in the order in which they
were enrolled.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All participants and medical, laboratory,
and statistical staff remained blinded to the
treatment allocation until all data collec-
tion had been completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All participants and medical, laboratory,
and statistical staff remained blinded to the
treatment allocation until all data collec-
tion had been completed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine participants were lost to follow-up,
6/98 in the steroid group and 3/99 in the
placebo group, representing 5% of the total
participants
Selective reporting (reporting bias) High risk The study protocol was not available. The
primary outcome was all-cause mortality
and this is clearly stated, but the other out-
comes are not specified in the introduction
or methods section
“The use of prednisolone was associated
with more-rapid improvement in all of the
principal symptoms and signs of pleural tu-
berculosis. This effect was statistically sig-
nificant, particularly during the first few
weeks of treatment, for anorexia, weight
loss, and cough (figure 3A-C).” Only data
related to the statistically significant out-
comes for symptomatic improvement are
reported
Other bias Low risk We did not identify any other potential
sources of bias.
Galarza 1995
Methods Location: Hospital Universitari de Bellvitge, Barcelona, Spain
Date: January 1985 and December 1992
Trial design: prospective, randomized, double blind, placebo controlled study
Follow-up: 6 months
Participants Number of participants (% female): 117, 58 (48%) female. 60 received placebo, 57
received prednisone. No losses to follow-up reported
Age: 11 to 53 years
Inclusion criteria: diagnosis of tuberculous pleurisy was made if patients met at least
one of the following criteria
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Galarza 1995 (Continued)
• Pleural exudate with positive culture for M. tuberculosis
• Pleural biopsy culture positive for M. tuberculosis
• Caseating granulomas with Langhans giant cells, epithelioid cells, and
lymphocytes
• Compatible clinico-radiological picture plus 2 or more of the following: Mantoux
test reaction of >6 mm or conversion using 5 units of tuberculin PPD-S, lymphocytic
pleural fluid (> 70% lymphocytes), pleural fluid levels of adenosine deaminase activity
(ADA) > 60 U/mL (reported in Cañete 1994)
Diagnostic algorithm: thoracocentesis with analysis of pleural biopsy and pleural fluid
Exclusion criteria: diagnostic investigations not consistent with the inclusion criteria,
HIV seropositive
HIV status: the trial excluded HIV-positive people
Interventions Intervention: prednisone plus standard regimen
Control: placebo plus standard regimen
Prednisone: single oral dose of 1 mg/kg/day for 15 days tapering off over the next 15
days
Standard regimen: isoniazid (5 mg/kg/day; max 300 mg/day); rifampicin (10 mg/kg/
day; max 600 mg/day); once daily as a combination tablet for 6 months
Outcomes • Time to resolution of fever
• Lung function assessed by forced vital capacity (FVC) at end of treatment
• Pleural thickening at baseline and at 1, 6, and 12 months after start of treatment
• Rate of reabsorption of pleural fluid on chest x-ray at baseline and at 1, 6, and 12
months after start of treatment
• Adverse effects
Notes Adefinitemicrobiological or pathological diagnosiswas confirmed in63%of participants
Before discharge, pleural fluid was drained until 1/3 of hemithorax was occupied on
standard chest X-ray in all participants
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of randomization
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients were randomly assigned to re-
ceive, in a double blind fashion, either pred-
nisolone or placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial authors did not mention the
blinding of outcome assessors
27Corticosteroids for tuberculous pleurisy (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Galarza 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors did not report any losses
to follow-up; therewere nounexplainedde-
faulters
Selective reporting (reporting bias) Low risk No protocol available, but the trial authors
reported on the 2 main outcomes specified
in the introduction
Other bias Low risk We did not identify any other source of
bias.
Lee 1988
Methods Location: Chang Gung Memorial Hospital, Taipei, Taiwan
Date: October 1983 with recruitment until June 1987
Trial design: double-blind, placebo-controlled, randomized study
Follow-up: up to 24 months
Participants Number of participants (% female): 45 recruited to study, 16/40 (40%) female. 40
participants included in analysis, 21 in steroid group, 19 in placebo group. Five par-
ticipants were excluded from the analysis, 1 due to a diagnosis of renal cell carcinoma
and 4 were lost to follow-up. The trial authors did not report which group the excluded
participants were randomized to
Age: mean age 28.7 years, range 18 to 45 years
Inclusion criteria: under 45 years, new pleural effusion not previously treated, with
pleural biopsy reported at TB or chronic granulomatous inflammation
Exclusion criteria: history of pulmonary TB, diagnosis of alternative cause of pleural
effusion such as heart failure, malignancy, pneumonia, history of other pulmonary dis-
ease or condition that contraindicated the use of steroids such as diabetes, peptic ulcer,
hypertension
HIV status: not reported
Interventions Intervention: prednisolone plus standard regimen
Control: placebo plus standard regimen
Prednisolone initially given as a single oral dose (0.75 mg/kg/day), tapered gradually
over 2 to 3 months once radiological improvement was seen by 5 mg per week until
discontinued
Standard regimen: isoniazid (300 mg/day); rifampicin (450 mg/day) for 9 to 12 months;
and ethambutol (20 mg/kg/day) for 3 months
Outcomes • Time to resolution of clinical symptoms
• Rate of reabsorption of pleural fluid on chest x-ray
• Pleural adhesions
• Adverse effects
Notes Diagnostic thoracocentesis (< 50 mL) performed on the first day for all participants; no
participants reported as having therapeutic thoracocentesis
Criteria for tapering prednisolone dose as follows
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Lee 1988 (Continued)
• Right-sided effusion with fluid level only one intercostal space higher than the left
hemidiaphragm
• Left-sided effusion with fluid level at the same height as the right hemidiaphragm
• Complete resolution of the effusion
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Those whowere eligible for the studywere
randomly assigned to treatment with either
prednisolone plus antituberculosis drugs
(steroid group) or placebo with antituber-
culosis drugs (placebo group.”
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial authors described this as “double
blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial authors did not mention whether
blinding of outcome assessors took place or
not
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial excluded 5 participants excluded
from the final analysis; 1 due to diagnosis
of renal cell carcinoma and 4 due to loss
to follow-up with no further information
given. Therefore the trial authors included
89% of recruited participants in the final
analysis. The trial authors did not report
which groups the five excluded participants
were randomized to
Selective reporting (reporting bias) Low risk There was no protocol available, but the
trial authors reported all outcomes that
they clearly stated in the methods
Other bias Low risk We did not identify any other sources of
bias.
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Lee 1999
Methods Setting: Chung-Ang University Hospital, South Korea
Date: February 1990 to February 1997
Trial design: prospective randomized study
Follow-up: participants were followed up at 2 months and 6 months, and in a final visit
to the out-patient department after treatment. Median follow-up was 9 months in the
steroid group and 12 months in the control group
Participants Number of participants: 82, 29 (35%) female; 32 participants in the steroid group and
50 in the control group. No losses to follow-up reported
Age: mean 32 years, range 17 to 51 years
Inclusion criteria: people admitted to hospital with a diagnosis of TB pleurisy based
on TB on pleural biopsy, or pleural effusion with AFB stain positive on microscopy of
sputum, pleural fluid, or pleural biopsy, or M. tuberculosis culture positive on sputum,
pleural fluid, or pleural biopsy. Pleural biopsy and diagnostic pleurocentesis were per-
formed on all patients on the 1st or 2nd day of admission
Exclusion criteria: people with pleural effusion due to other causes (not specified by the
trial authors). People with diabetes, hypertension, or peptic ulcer disease who could not
receive corticosteroids. People who were ”not cooperative“
HIV status: not mentioned.
Interventions Intervention: ATT plus prednisolone 30 mg once daily for 1 month and then tapered
over the following month.
Control: ATT alone. ATT regimen: isoniazid, rifampicin, pyrazinamide, and ethambu-
tol for 6 months or isoniazid, rifampicin, pyrazinamide, and streptomycin for 2 months
followed by same regimen minus streptomycin for 4 months; dosage not stated
Outcomes • Time to resolution of pleural effusion
• Development of pleural adhesions, defined as lack of resolution of pleural effusion
on chest x-ray up to final visit
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The trial did not state the method of ran-
domization, and the number of partici-
pants in each group appears imbalanced
(steroid group N = 50, control group N =
32). “… patients were randomized to the
steroid group and the non-steroid group”
Allocation concealment (selection bias) Unclear risk The trial authors did not report on the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial authors did not report on blinding
of participants and personnel
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Lee 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial did not report on blinding of out-
come assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up.
Selective reporting (reporting bias) Low risk The trial protocol was unavailable, but the
trial authors reported all outcomes specified
in the introduction in the results
Other bias Low risk We did not identify any other sources of
bias.
Wyser 1996
Methods Setting: Tygerberg Hospital, Cape Town, South Africa
Date: April 1994 with recruitment until January 1995
Trial design: double-blind, placebo-controlled, randomized study
Follow-up: 6 months
Participants Number of participants (% female): 74 participants randomized, 70 included in anal-
ysis, 36 in placebo group, 34 in prednisone group, 27/70 (36.5%) female. The trial
authors excluded 4 participants from analysis, 3 due to non-compliance with treatment,
1 due to diagnosis of oesophageal cancer at follow-up. The trial authors did not report
to which group the excluded participants were randomized to
Age: mean age 33 years
Inclusion criteria: pleural biopsy specimen proving TB pleurisy, based on presence of
caseating granulomata with or without AFB on histological examination, or a positive
culture for M. tuberculosis.
Diagnostic algorithm: thoracoscopy followed by bronchoscopy under general anaes-
thesia, with biopsies of the parietal pleura taken for histological examination and culture
Exclusion criteria: people with other causes of exudative effusion such as pneumonia
or cancer. People with contraindications to corticosteroids such as diabetes mellitus,
uncontrolled hypertension, peptic ulcer disease, and empyema. People with HIV
HIV status: the trial authors excluded HIV-positive people.
Interventions • Prednisone plus standard regimen
• Placebo plus standard regimen
Prednisone: oral dose of 0.75 mg/kg/day for 2 to 4 weeks; dose tapered by 5 mg/day
over 2 weeks after clinical and radiological improvement
Standard regimen: isoniazid (8 mg/kg/day), rifampicin (10 mg/kg/day), and pyrazi-
namide (25 mg/kg/day) as a fixed combination tablet (Rifater); and pyridoxine (25 mg/
kg/day) for 6 months
Outcomes • Resolution of symptoms: dyspnoea, cough, night sweats, tiredness, appetite,
pleuritic chest pain, and general well-being were each graded from 0 to 100 using a
visual analogue scale and combined index with a maximum score of 700 was calculated
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• Lung function at end of treatment as assessed by total lung capacity (TLC) and
FVC
• Recurrence of effusion
• Residual pleural thickening at 24 weeks
• Adverse effects
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All eligible patients were randomly as-
signed in a double-blind fashion to treat-
ment with either prednisone plus stan-
dard anti-TB therapy (prednisone group)
or placebo plus standard anti-TB therapy
(placebo group).”
Allocation concealment (selection bias) Unclear risk The trial described the placebo tablets as
“identical”. The trial authors did not clearly
describe the method of concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial authors described the trial as “dou-
ble blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessors were “blinded to the
clinical history”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors excluded four participants
from the analysis; 3 due to “non-compli-
ance with the treatment”
Selective reporting (reporting bias) Low risk The protocol was unavailable, but the trial
authors reported the outcomes described in
the introduction
Other bias Low risk We did not identify any other source of
bias.
Abbreviations: AFB: acid-fast bacilli; ATT: antituberculous treatment; FVC: forced vital capacity; HIV: human immunodeficiency
virus; TB: tuberculosis.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aspin 1958 No randomization
Bilaceroglu 1999 Participants did not have pleurisy - cases of pulmonary tuberculosis (TB)
Cherednikova 1973 Case series
Cisneros 1996 Review
Damany 1968 Numbers of participants in each trial arm not clearly stated
Filler 1963 No randomization
Fleishman 1960 Diagnosis of TB not confirmed
Grewal 1969 No randomization
Khomenko 1990 Participants did not have pleurisy - cases of pulmonary TB
Manresa 1997 Letter referring to included trial (Galarza 1995)
Mansour 2006 No randomization
Mathur 1960 No randomization
Mathur 1965 No randomization
Mayanja-Kizza 2005 Participants did not have pleurisy - cases of pulmonary TB
Menon 1964 No randomization
Paheco 1973 Compared prednisolone to another steroid (cortivazol)
Paley 1959 No randomization
Porsio 1966 Participants did not have pleurisy - cases of pulmonary TB
Singh 1965 No randomization
Starostenko 1989 No randomization
Tani 1964 No randomization
Tanzj 1965 No randomization
Abbreviations: TB: tuberculosis.
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Characteristics of ongoing studies [ordered by study ID]
ChiCTR-TRC-10000747
Trial name or title A multi-center, randomized, double-blind, parallel placebo trial to evaluate the clinical efficacy of glucocor-
ticosteroid for tuberculous pleurisy
Methods Interventional randomized parallel control trial
Participants Inclusion criteria
• Male or female, aged between 18 to 65 years
• Presented with typical clinical features and signs suggesting pleurisy
• Willing to join the study and signs informed consent form
• Consistent with the diagnosis criteria in patients with tuberculous pleurisy
Exclusion criteria
• Severe cardiac diseases,lung diseases, hematological diseases, malignant tumor, hypoimmunity diseases,
mental diseases, diabetes
• Digestive system diseases, such as peptic ulcer or alimentary tract haemorrhage
• Abnormal of blood-fasting sugar or postprandial blood sugar (2 hours)
• Chronic liver diseases,such as viral hepatitis type B or C
• Chronic hepatic or renal inadequacy (ALT>1.5 upper limits of normal; Cr > upper limits of normal)
• Alcohol or drug abuse
• Package chest or pachynsis pleurae
• Course of disease > 14 days
• Antituberculous therapy > 30 days
• Woman either pregnant or lactating
• Have accepted glucocorticosteroid
• Participate in other clinical trials within 3 weeks
• Contraindication to glucocorticosteroid
Target sample size: Group A: 500; Group B: 500; Total: 1000
Interventions Group A: prednisone orally taken 30 mg once daily for 2 weeks, then reduce to 20 mg once daily for 3rd
week; finally reduce to 10 mg for 4th week;
Group B: placebo orally taken 30 mg once daily for 2 weeks, then reduce to 20 mg once daily for 3rd week;
finally reduce to 10 mg for 4th week
Outcomes Primary outcome
• Rate of pleura thickening
Secondary outcome
• Time of pleural thickening;
• Time of pleural effusion absorption
Starting date Date of first enrolment: 1 January 2010
Last refreshed: 29 June 2014
Contact information HuangzhongShi,Department ofRespiratory ofWuhanUnionHospital,No. 1277LiberationAvenue,Wuhan
430022. Tel: +86 027 85726010. Email: xinjbwh@163.com
JIianbo Xin, Department of Respiratory of Wuhan Union Hospital, No. 1277 Liberation Avenue, Wuhan
430022. Tel: +86 027 85726757. Email: xinjbwh@163.com
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ChiCTR-TRC-10000747 (Continued)
Notes Sponsors:WuhanUnionHospital; National Science Fund forDistinguished Young Scholars, NationalNatural
Science Foundation of China
Trial is identical to ChiCTR-TRC-09000747 (www.chictr.org.cn/showproj.aspx?proj=8789)
We contacted the trial authors for further information but did not receive a response to date
NCT00338793
Trial name or title A Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy and
Safety of Corticosteroids for Treatment of Patients With Tuberculous Pleurisy
Methods Interventional double-blinded randomized parallel safety/efficacy study
Participants Inclusion criteria
• Male or female, over 18 years of age
• Signed written informed consent
• Presented with clinical features suggesting pleural tuberculosis
• Had not previously received treatment or prophylaxis for tuberculosis
• Had not recently received treatment with glucocorticoids
• Were not pregnant or breast-feeding
Exclusion criteria
• Failed to complete the screening procedures
• Were seropositive for HIV
• Tuberculous meningitis
• Had risk factors for serious steroid-related adverse events (a history of diabetes or positive urine
glucose, a history or clinical finding of hypertension, or a history of peptic ulcer disease or mental illness)
• Standard doses of antituberculosis drugs could not be used (as in participants with concurrent liver
disease)
• Psychiatric illness
• Alcoholism
Target sample size: 1500
Interventions Prednisolone versus placebo
Outcomes Primary outcomes
• Adverse drug effects
• Death
• Presence of pleural thickening
• Pulmonary function at completion of treatment
Secondary outcomes
• Failure rate at the end of treatment
• Improvement in clinical symptoms and signs (such as pleuritic chest pain, temperature)
• Reabsorption of pleural effusion
Starting date Date of registration: 19 June 2006
Date of first enrollment: July 2006
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Contact information Xin Zhou, MD, Department of Respiratory Diseases, First Affiliated Hospital, Shanghai Jiaotong University,
Shanghai, China
Zhan-Cheng Gao, MD, PhD, Department of Respiratory Diseases, People’s Hospital, Peking University,
Beijing, China
Huan-Zhong Shi, MD, PhD, Institute of Respiratory Diseases, First Affiliated Hospital, Guangxi Medical
University, Nanning 530021, Guangxi, China
Notes Sponsors: Guangxi Medical University; Bureau of Science and Technology of Guangxi Province, China;
Ministry of Education, China; National Natural Science Foundation of China
Recruitment completed.
We contacted the trial authors but have not received a reply to date
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroids versus control (placebo or no steroids)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Residual pleural effusion on
chest X-ray
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 4 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.84]
1.2 At 8 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.37, 0.78]
1.3 At 24 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.18, 0.66]
2 Pleural changes at the end of
treatment (pleural thickening
and pleural adhesions)
5 393 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.57, 0.92]
3 Death from any cause 1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.64, 1.31]
4 Adverse events leading to study
drug discontinuation
6 590 Risk Ratio (M-H, Fixed, 95% CI) 2.78 [1.11, 6.94]
5 HIV-associated adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Cryptococcal meningitis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Oesophageal candidiasis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Oral candidiasis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Gastroenteritis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Herpes simplex 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Herpes zoster 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Kaposi sarcoma 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Effect of study quality on the outcome residual pleural fluid on chest X-ray
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Residual pleural fluid on chest
X-ray - studies at high risk of
selection bias excluded
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 4 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.84]
1.2 At 8 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.37, 0.78]
1.3 At 24 weeks 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.18, 0.66]
2 Residual pleural fluid on chest
X-ray - studies at high risk of
selection bias included
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 At 4 weeks 3 321 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.52, 1.07]
2.2 At 8 weeks 4 403 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.47, 1.12]
2.3 At 24 weeks 4 403 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.30, 0.98]
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A D D I T I O N A L T A B L E S
Table 1. Theoretical framework describing differences between isolated tuberculous pleurisy and pulmonary TB with tuber-
culous pleurisy (pleuro-pulmonary TB)
Clinical Feature Isolated pleural TB Pleuro-pulmonary TB
Sputum microscopy/culture Negative Some positive
Pleural fluid Usually demonstrates exudative effusion
Usually negative for M. tuberculosis on smear
and culture
Usually demonstrates exudative effusion
Usually negative for M. tuberculosis on smear
and culture
Chest X-ray Discrete pleural effusion, or pleural thicken-
ing, or both
Pleural effusion with other changes such as
consolidation, cavities, atelectasis, or hilar en-
largement
Chest computed tomography (CT) May demonstrate underlying lung infection Demonstrates underlying lung infection
Pathogenesis Predominantly driven by delayed type hyper-
sensitivity reaction
Predominantly driven by TB infection of the
lung
Prognosis Most people will improve with no antituber-
culous treatment (ATT), but may experience
a relapse of TB infection
People may deteriorate and die without ATT
Table 2. Summary of characteristics of included studies
Trial Country Year Participants Adults or
children
HIV status ATT
regimen
Therapeu-
tic thoraco-
centesis
performed
Steroid
group
Control
group
Bang 1997 South Korea 1991 to
1994
34 50 Adults Not
reported
2RHZE/
7RHE
No
Elliott 2004 Uganda 1998 to
2002
99 98 Adults Positive 2RHZE/
4RH
No
Galarza
1995
Spain 1985 to
1992
57 60 Both Negative 6RH Yes
Lee 1988 Taiwan 1983 to
1987
21 19 Adults Not
reported
3RHE/6-
9RH
No
Lee 1999 South Korea 1990 to
1997
50 32 Adults Not
reported
6RHZE
or 2RHZS/
4RHZ
No
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Table 2. Summary of characteristics of included studies (Continued)
Wyser 1996 South Africa 1994 to
1995
34 36 Adults Negative 6RHZ Yes
Abbreviations: ATT: antituberculous treatment; E: ethambutol; H: isoniazid; R: rifampicin; S: streptomycin; Z: pyrazinamide.
Table 3. Diagnostic testing in included trials
Trial Diagnostic criteria for pleural TB Other diagnostic tests
Bang 1997 Microscopy positive for AFB or culture positive from spu-
tum, pleural fluid, or pleural biopsy
• Chest X-ray
Elliott 2004 Positive culture from pleural biopsy, pleural fluid, or spu-
tum, or histopathologic analysis of pleural biopsy consis-
tent with tuberculous pleurisy
• Chest X-ray
• HIV test (rapid test and ELISA)
• Serum cryptococcal antigen test
• CD4+ cell count
• HIV viral load (plasma and pleural fluid)
• Serum glucose
Galarza 1995 At least one of the following
• Pleural exudate with positive culture
• Pleural biopsy culture positive
• Pleural biopsy with caseating granulomas with
Langhans giant cells,
• Epithelioid cells and lymphocytes
• Compatible clinico-radiological picture plus 2 or
more of the following:
◦ age < 40 years, PPD > 6 mm or conversion
using 5 units of tuberculin PPD-S, lymphocytic pleural
fluid (> 70% lymphocytes), pleural fluid levels of
adenosine deaminase activity (ADA) > 60 U/mL
• Chest X-ray
• Simple spirometry (FVC and FEV1)
• Serum biochemistry
• Full blood count
• HIV test
Lee 1988 Pleural biopsy reported as pleural TB or chronic granu-
lomatous inflammation
• Chest X-ray
• Unspecified diagnostic tests to exclude heart
failure, malignancy, pneumonia, diabetes mellitus
• Chest ultrasound or CT scan in participants with
persisting pleural effusion after 3 months
Lee 1999 TB on pleural biopsy, or pleural effusion plus AFB stain
positive or culture positive from sputum, pleural fluid, or
pleural biopsy
• Chest X-ray
Wyser 1996 Pleural biopsy with caseating granulomata with or with-
out AFB on histological examination, or positive culture
• Chest X-ray
• Unspecified tests to rule out pneumonia,
empyema, malignancy, diabetes mellitus
• HIV test
• Thoracoscopy and bronchoscopy performed under
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Table 3. Diagnostic testing in included trials (Continued)
general anaesthesia
• High-resolution CT chest at three levels to measure
pleural thickness
• Spirometry and body plethysmography
Abbreviations: ADA: adenosine deaminase activity; AFB: acid-fast bacilli; CT: computed tomography; ELISA: enzyme-linked im-
munosorbent assay; FEV1: forced expiratory volume at one second; FVC: forced vital capacity; HIV: human immunodeficiency
virus; PPD: purified protein derivative; PPD-S: purified protein derivative-standard; TB: tuberculosis
Table 4. Corticosteroid regimens in included studies
Trial Steroid Regimen
Bang 1997 Prednisolone 1 mg/kg twice daily, tapered by 10 mg each week until cessation
Elliott 2004 Prednisolone 50 mg daily for 2 weeks, 40 mg daily for 2 weeks, then 25 mg daily for 2 weeks, then 15 mg daily
for 2 weeks, then stopped
Galarza 1995 Prednisone 1 mg/kg/day for 15 days, tapering over the next 15 days
Lee 1988 Prednisolone 0.75 mg/kg/day, tapered by 5 mg per week until discontinued once radiological improvement was
seen
Lee 1999 Prednisolone 30 mg four times daily for 1 month and tapered over the following month
Wyser 1996 Prednisone 0.75 mg/kg/day for 2 to 4 weeks; dose tapered by 5mg/day over 2 weeks after clinical and radiological
improvement
Abbreviations: mg: milligrams
Table 5. Results: Time to resolution of symptoms
Trial Indicator Units Corticosteroids Control
Mean values Bang 1997 “Fever, pleuritic pain,
malaise and breath-
lessness”
Mean days to resolu-
tion
3.8 (N = 34) 7.41 (N = 50)
Galarza 1995 “Fever duration” Mean days 3.32 (N = 57) 4.15 (N = 60)
Lee 1988 “Fever, pleuritic pain,
malaise and breath-
lessness”
Mean days to resolu-
tion
2.4 (N = 21) 5.6 (N = 19)
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Table 5. Results: Time to resolution of symptoms (Continued)
Cut-offs (categori-
cal)
Elliott 2004 “Anorexia” Number of partici-
pants with anorexia at
4 weeks
3/99 (3%) 18/98 (18.4%)
“Cough” Number of partici-
pants with cough at 4
weeks
35/99 (35.4%) 57/98 (58.2%)
“Weight” Mean weight in kg at
4 weeks
57 52.5
Wyser 1996 Symptoms
resolved in all patients
(VAS score)
Weeks 12 16
Abbreviations: kg: kilograms; VAS: visual analogue scale
1P < 0.05.
Table 6. Time to resolution of pleural effusion on chest X-ray
Trial Units Corticosteroids Control
Mean values Bang 1997 Mean days to resolution 88 (N=34) 100 (N=50)
Lee 1988 Mean days to resolution 54.5 (N=21) 123.2 (N=19)
Galarza 1995 Reabsorption index1 at 4
weeks
93% 89%2
Categorical values Bang 1997 Number of participants with
residual effusion at 4 weeks
26/34 (76.5%) 39/50 (78%)
Number of participants with
residual effusion at 8 weeks
19/34 (55.9%) 30/50 (60%)
Number of participants with
residual effusion at 24 weeks
2/34 (5.9%) 3/50 (6%)
Elliott 2004 Number of participants with
residual effusion at 4 weeks
38/99 (38.4%) 56/98 (57.1%)
Number of participants with
residual effusion at 8 weeks
25/99 (30.3%) 42/98 (56.1%)
Number of participants with
residual effusion at 24 weeks
10/99 (10.1%) 25/98 (25.5%)3
Lee 1988 Number of participants with
residual effusion at 4 weeks
9/21 (42.9%) 15/19 (78.9%)
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Table 6. Time to resolution of pleural effusion on chest X-ray (Continued)
Number of participants with
residual effusion at 8 weeks
5/21 (23.8%) 12/19 (63.2%)
Number of participants with
residual effusion at 24 weeks
1/21 (4.8%) 6/19 (31.6%)
Lee 1999 Number of participants with
residual effusion at 8 weeks
29/32 (90.6%) 49/50 (98%)
Number of participants with
residual effusion at 24 weeks
20/32 (62.5%) 44/50 (88%)
Abbreviations: N: number of participants
1Reabsorption index = (length of affected hemithorax/length of healthy hemithorax) x 100.
2P = 0.01.
3Data at this time point extrapolated from graph. Data for 4 weeks and 8 weeks from the trial authors (unpublished data).
Table 7. Pulmonary function at the end of treatment
Trial Indicator Units Corticosteroids Control
Galarza 1995 Percentage predicted FVC Mean percentage predicted
FVC
95% (N = 57) 95% (N = 60)1
Wyser 1996 Percentage predicted FVC Mean percentage predicted
FVC
85% (N = 34) 80% (N = 36)2
Lung function impairment Number of participants
with restrictive PFT results
11/34 (33.3%) 14/36 (39.4%)3
Abbreviations: FVC: forced vital capacity; N: number of participants; PFT: pulmonary function tests
1Range 65% to 130% in steroid group, 63% to 140% in placebo group.
2Read from graph, P = 0.65.
3P = 0.72. Results extrapolated from percentages.
Table 8. Adverse events leading to discontinuation of the trial drug
Trial Corticosteroid Control
Bang 1997 1/34 (2.9%)1 0/50
Elliott 2004 9/99 (9.1%)2 2/98 (2.0%)
Galarza 1995 0/57 NR
Lee 1988 1/21 (4.8%)3 NR
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Table 8. Adverse events leading to discontinuation of the trial drug (Continued)
Lee 1999 NR NR
Wyser 1996 4/34 (11.8%) 3/36 (8.3%)4
Abbreviations: NR: not reported
1Aggravation of epigastric pain in one patient, steroids stopped, and patient withdrawn from the trial.
2Trial drug discontinued for hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants),
oesophageal candidiasis (one participant) in the corticosteroid group; in the placebo group hyperglycaemia (one participant) and
hypertension (one participant).
3One participant developed moon facies, epigastric pain, and lower limb oedema, all of which resolved on tapering the dosage.
4Epigastric pain was the only adverse effect noted, and affected four participants in the steroid group and three in the control group.
Table 9. Results: HIV-related adverse events
Trial Indicator Control (N/98) Corticosteroid (N/99)
Elliott 2004 Kaposi’s sarcoma 0 6 (6.1%)
Cryptococcal meningitis 5 (5.1%) 3 (3.0%)
Oesophageal candidiasis 23 (23.5%) 35 (35.4%)
Oral candidiasis 31 (32.6%) 31 (31.3%)
Herpes zoster 19 (19.4%) 22 (22.2%)
Oral or genital herpes simplex 20 (20.4%) 22 (22.2%)
Gastroenteritis 28 (28.6%) 34 (34.3%)
Abbreviations: N: number of participants
WH A T ’ S N E W
Last assessed as up-to-date: 18 November 2016.
Date Event Description
20 February 2017 New search has been performed Complete new edition, with a new protocol, fresh data
extraction, GRADE assessment of the certainty of evi-
dence, and a new review author team
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(Continued)
20 February 2017 New citation required but conclusions have not
changed
We updated the review updated with a new review au-
thor team.Weperformed anew literature search;we did
not include any new trials. We revised the Background
section. Also, we amended the objective and selection
criteria. The review authors performed data extraction
and ’Risk of bias’ assessments.We included a ’Summary
of findings’ table and performed GRADE assessments.
Also we revised the Results and Discussion sections.
H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 3, 1998
Date Event Description
10 September 2008 Amended Converted to new review format with minor editing.
24 July 2007 New citation required and conclusions have changed Review title changed from ’Steroids for treating tuber-
culous pleurisy’; search updated to May 2007; general
updates and modifications weremade tomost sections
with the methods and results sections of the review
entirely revised; ’Types of interventions’ modified to
include any corticosteroid used in combination with
antituberculos treatment; ’Types of outcomemeasures’
modified to evaluate death from any cause and im-
provement in respiratory function as primary out-
comes, secondary outcomes updated to include HIV-
associated events, “worsening of the parenchymal dis-
ease” excluded, and adverse drug effects changed to
adverse events. Three new trials added, one of which
consisted exclusively ofHIV-positive participants. De-
spite all this, the conclusions remain unchanged
28 April 2006 Amended New studies sought but none found.
28 February 2005 Amended New studies found and included or excluded.
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C O N T R I B U T I O N S O F A U T H O R S
HR and PD refreshed the protocol and performed the selection of studies. HR, PD, and YJ extracted data and performed ’Risk of bias’
assessments for the included trials. HR revised the Background, Methods, Results, and Discussion sections, with input from PD and
YJ.
D E C L A R A T I O N S O F I N T E R E S T
HR was employed by the Cochrane Infectious Diseases Group, which is funded by a grant from the UK Government DFID.
PD is employed by the National Institute for Research in Tuberculosis, Chennai, a permanent institute under the Indian Council of
Medical Research, which is funded by the Government of India through the Ministry of Health and Family Welfare.
HR and PD conducted the preliminary work that contributed to the conception and design of this Cochrane Review as part of the
evidence reviewprocess for the IndianExtra-PulmonaryTB (INDEX-TB)Guidelines, a guideline for extrapulmonary TB commissioned
by the Ministry of Health and Family Welfare, Government of India. Global Health Advocates funded this guideline, and the All India
Institute of Medical Sciences, New Delhi convened it.
S O U R C E S O F S U P P O R T
Internal sources
• South African Medical Research Council, South Africa.
• University of Cape Town, South Africa.
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We updated this review with the aim of adding any new evidence that may have been published since the previous search in 2007. For
this version, we revised the protocol, and in particular altered the outcomes of interest. This was informed by discussions with expert
clinicians which took place during the development of a new guideline on extrapulmonary TB in India, the INDEX-TB guidelines
(INDEX-TB 2016).
N O T E S
There is a discrepancy between the number of participants across all the trials in this update and the previous version (Engel 2007).
This is because the data extraction was done again using a different data extraction tool.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗therapeutic use]; Randomized Controlled Trials as Topic; Tuberculosis, Pleural [∗drug therapy]; Tuber-
culosis, Pulmonary [drug therapy]
MeSH check words
Humans
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